Proteomics advances for precision therapy in ovarian cancer

Area of Science:

• Oncology
• Proteomics
• Genomics

Background:

• High-grade serous carcinoma (HGSC) presents challenges for identifying genetic drivers due to low mutation rates and high copy number variation.
• Genetic alterations in HGSC are often not well-represented at the protein level, complicating therapeutic target identification.
• Large-scale proteomic technologies offer a powerful approach to analyze pathways driving HGSC.

Purpose of the Study:

• To review recent large-scale proteomics findings in ovarian cancer.
• To explore the potential of proteomics in identifying therapeutic targets and understanding adaptive responses in HGSC.
• To highlight the need for integrating genomic, epigenomic, and proteomic data for improved patient outcomes.

Main Methods:

• Literature review of large-scale proteomics studies in ovarian cancer.
• Systematic search of PubMed using keywords: 'ovarian cancer', 'proteomics', 'proteogenomic', 'reverse-phase protein array', 'mass spectrometry', and 'adaptive response'.

Main Results:

• Proteomics studies are increasingly important for understanding HGSC.
• Analysis of proteomic data can reveal new therapeutic vulnerabilities in HGSC.
• Understanding protein-level heterogeneity is key to addressing treatment resistance.

Conclusions:

• Proteomics analysis of HGSC, including adaptive responses to therapy, can uncover novel therapeutic targets.
• Addressing the gap between genomic/epigenomic data and protein expression is critical for improving patient outcomes in ovarian cancer.
• Integrating proteomic insights holds promise for reducing drug resistance and enhancing treatment efficacy in HGSC.